Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
This MoU marks a significant milestone in interdisciplinary research, paving the way for scientific advancements in homoeopathy
Encourages working women to practice self-care
Overall investment in the US facility is estimated around US$50 million
403 entries from 22 states covering 168 districts highlight groundbreaking initiatives vital to improving national nutrition metrics.
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
Nadda also commended the role of ASHA workers, “grassroot foot soldiers”, in the healthcare system
Melicica has potential applications in skin repair, scar and acne-prone skin care, tone evening and brightening, texture improvement, baby care, sensitive skin solutions, post-procedure recovery and stretch mark care
In financial year 2024-25, PMBJP has made sales of Rs. 1,760 crore (at MRP) till Feb 2025
Subscribe To Our Newsletter & Stay Updated